An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control.

HB 1439 amends Pennsylvania's Controlled Substance, Drug, Device and Cosmetic Act. The bill requires that the pharmaceutical composition of crystalline polymorph psilocybin be scheduled in Pennsylvania to match federal law immediately upon its approval by the United States Food and Drug Administration. Following federal rescheduling by the U.S. Drug Enforcement Administration, the state Secretary of Health must publish notice of this change. The state's rescheduling of this substance will then take effect 30 days after its publication in the Pennsylvania Bulletin. This process directly affects the legal classification of this specific substance within the Commonwealth.